Jun 2026 (Q2 FY26) — Aug 6, 2026
Amphastar Q2 FY26 — Strong Commercial Portfolio Performance and Pipeline Advancement
Read the full callAmphastar (AMPH) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Amphastar earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 184 | +5.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 21.6 | −2.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 30.3 | −2.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$26.14 +1.04% · +$0.27
Performance +9.9% 1Y
1Y: $23.78 on 17 Oct 2025 → $26.14. High $29.4 (12 Jan 2026), low $16.87 (15 May 2026).
- Previous close
- $25.87
- 52-week range
- $16.87 – $29.4
- One year
- +10.16%
Overview
- Symbol
- AMPH
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Amphastar earnings calls (AMPH)
Financials
What the filings say
Net profit, year on year: −2% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 191 | 187 | 171 | 174 | 192 | 183 | 171 | 184 |
| Operating profit | 57 | 45 | 37 | 42 | 25 | 36 | 14 | 40 |
| Operating margin | 29.8% | 24.2% | 21.9% | 24.2% | 13.2% | 19.4% | 8.0% | 21.6% |
| Other income | -9 | -1 | -6 | -3 | -4 | -4 | -4 | -1 |
| Interest | 7 | 6 | 6 | 6 | 6 | 7 | 7 | 7 |
| Profit before tax | 48 | 44 | 31 | 39 | 22 | 32 | 10 | 39 |
| Tax rate | 15.2% | 13.6% | 18.1% | 21.1% | 19.4% | 23.4% | 36.1% | 21.3% |
| Net profit | 40 | 38 | 25 | 31 | 17 | 24 | 6 | 30 |
| EPS ($ per share) | 0.83 | — | 0.53 | 0.66 | 0.38 | — | 0.14 | 0.69 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 67 | 116 | 118 | 180 | 272 | 409 | 569 | 667 |
| Total liabilities | 149 | 159 | 183 | 226 | 213 | 873 | 845 | 840 |
| Fixed assets | 210 | 234 | 260 | 244 | 238 | 283 | 297 | 311 |
| Investments | 3 | 12 | 13 | 10 | 20 | 113 | 70 | 113 |
| Total assets | 514 | 587 | 631 | 672 | 742 | 1,513 | 1,577 | 1,629 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 38 | 42 | 57 | 98 | 89 | 184 | 213 | 156 |
| Cash from investing | -42 | -51 | -36 | -29 | -33 | -649 | -125 | -70 |
| Cash from financing | 25 | -4 | -2 | -37 | -26 | 454 | -81 | -67 |
| Net cash flow | 21 | -13 | 19 | 32 | 30 | -12 | 7 | 19 |
| Capital expenditure | -47 | -42 | -34 | -27 | -24 | -38 | -41 | -35 |
| Free cash flow | -9 | 0 | 23 | 71 | 65 | 145 | 172 | 121 |
Insider filings
49 filings between Nov 3, 2025 and Sep 21, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$1.70M
11 sales by 4 insiders
27% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 12
- Award — granted as compensation
- 5
- Option exercise — converted options into shares
- 21
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Zhou Rong | — | $571.1K | Sep 16, 2026 |
| Petersen Floyd F. | — | $562.0K | Dec 12, 2025 |
| PETERS WILLIAM J | — | $287.4K | Sep 21, 2026 |
| PRINS RICHARD K | — | $275.1K | Aug 11, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 21, 2026 | PETERS WILLIAM J CFO, EVP & TREASURER | Sale 10b5-1 plan | 4,139 | $103.5K |
| Sep 16, 2026 | Zhou Rong SENIOR EVP, PRODUCTION CENTER | Sale | 10,000 | $239.4K |
| Sep 16, 2026 | Zhou Rong SENIOR EVP, PRODUCTION CENTER | Option exercise | 10,000 | $133.5K |
| Sep 2, 2026 | Zhou Rong SENIOR EVP, PRODUCTION CENTER | Sale | 3,187 | $75.3K |
| Aug 11, 2026 | PRINS RICHARD K Director | Sale | 7,973 | $161.9K |
| Aug 7, 2026 | PETERS WILLIAM J CFO, EVP & TREASURER | Option exercise 10b5-1 plan | 5,053 | $100.0K |
| Aug 7, 2026 | PETERS WILLIAM J CFO, EVP & TREASURER | Sale 10b5-1 plan | 8,180 | $183.9K |
| Jul 9, 2026 | Pierce Anthony T Director | Award | 7,886 | $0 |
| Jun 2, 2026 | Lee Howard Director | Tax withheld | 769 | $14.2K |
| Jun 1, 2026 | Gaugh David Russell Director | Award | 8,143 | $0 |
| Jun 1, 2026 | Lee Howard Director | Award | 8,143 | $0 |
| Jun 1, 2026 | PRINS RICHARD K Director | Award | 8,143 | $0 |
| Jun 1, 2026 | Deflin Gayle Director | Award | 8,143 | $0 |
| Jun 1, 2026 | ZASLOFF MICHAEL A Director | Award | 8,143 | $0 |
| Jun 1, 2026 | Gerst Diane G. Director | Award | 8,143 | $0 |
| Mar 15, 2026 | Zhang Jack Y. CEO & CHIEF SCIENTIFIC OFFICER | Tax withheld | 9,784 | $177.9K |
| Mar 15, 2026 | PETERS WILLIAM J CFO, EVP & TREASURER | Tax withheld | 1,973 | $35.9K |
| Mar 15, 2026 | Zhang Jack Y. CEO & CHIEF SCIENTIFIC OFFICER | Tax withheld | 2,908 | $52.9K |
| Mar 15, 2026 | Liawatidewi Yakob EVP CORP ADMIN CENTER | Tax withheld | 1,033 | $18.8K |
| Mar 15, 2026 | Zhou Rong SENIOR EVP, PRODUCTION CENTER | Tax withheld | 1,225 | $22.3K |
| Mar 10, 2026 | Liawatidewi Yakob EVP CORP ADMIN CENTER | Tax withheld | 1,870 | $35.4K |
| Mar 10, 2026 | Zhou Rong SENIOR EVP, PRODUCTION CENTER | Tax withheld | 2,215 | $41.9K |
| Mar 10, 2026 | PETERS WILLIAM J CFO, EVP & TREASURER | Tax withheld | 3,297 | $62.3K |
| Mar 10, 2026 | Zhang Jack Y. CEO & CHIEF SCIENTIFIC OFFICER | Tax withheld | 4,395 | $83.1K |
| Mar 10, 2026 | Zhang Jack Y. CEO & CHIEF SCIENTIFIC OFFICER | Tax withheld | 14,785 | $279.6K |
| Mar 9, 2026 | Zhou Rong SENIOR EVP, PRODUCTION CENTER | Award | 39,432 | $0 |
| Mar 9, 2026 | Liawatidewi Yakob EVP CORP ADMIN CENTER | Award | 35,450 | $0 |
| Mar 9, 2026 | PETERS WILLIAM J CFO, EVP & TREASURER | Award | 58,693 | $0 |
| Mar 9, 2026 | Zhang Jack Y. CEO & CHIEF SCIENTIFIC OFFICER | Award | 72,462 | $0 |
| Mar 9, 2026 | Zhang Jack Y. CEO & CHIEF SCIENTIFIC OFFICER | Award | 180,504 | $0 |
| Mar 6, 2026 | Zhou Rong SENIOR EVP, PRODUCTION CENTER | Tax withheld | 1,357 | $26.2K |
| Mar 6, 2026 | PETERS WILLIAM J CFO, EVP & TREASURER | Tax withheld | 2,146 | $41.5K |
| Mar 6, 2026 | Zhang Jack Y. CEO & CHIEF SCIENTIFIC OFFICER | Tax withheld | 3,077 | $59.5K |
| Mar 6, 2026 | Zhang Jack Y. CEO & CHIEF SCIENTIFIC OFFICER | Tax withheld | 7,773 | $150.3K |
| Mar 6, 2026 | Liawatidewi Yakob EVP CORP ADMIN CENTER | Tax withheld | 1,144 | $22.1K |
| Mar 4, 2026 | Zhou Rong SENIOR EVP, PRODUCTION CENTER | Tax withheld | 1,124 | $22.4K |
| Mar 4, 2026 | Zhang Jack Y. CEO & CHIEF SCIENTIFIC OFFICER | Tax withheld | 2,432 | $48.5K |
| Mar 4, 2026 | Liawatidewi Yakob EVP CORP ADMIN CENTER | Tax withheld | 965 | $19.3K |
| Mar 4, 2026 | Zhang Jack Y. CEO & CHIEF SCIENTIFIC OFFICER | Tax withheld | 5,769 | $115.1K |
| Mar 4, 2026 | PETERS WILLIAM J CFO, EVP & TREASURER | Tax withheld | 1,744 | $34.8K |
| Dec 17, 2025 | Zhou Rong SENIOR EVP, PRODUCTION CENTER | Option exercise | 9,787 | $110.9K |
| Dec 17, 2025 | Zhou Rong SENIOR EVP, PRODUCTION CENTER | Sale | 9,787 | $256.4K |
| Dec 12, 2025 | Petersen Floyd F. Director | Sale | 2,426 | $62.9K |
| Dec 11, 2025 | Petersen Floyd F. Director | Sale | 1,737 | $44.6K |
| Nov 25, 2025 | PRINS RICHARD K Director | Option exercise | 4,179 | $69.7K |
| Nov 25, 2025 | PRINS RICHARD K Director | Sale | 4,179 | $113.3K |
| Nov 13, 2025 | Petersen Floyd F. Director | Sale | 16,679 | $441.8K |
| Nov 13, 2025 | Petersen Floyd F. Director | Option exercise | 16,679 | $278.4K |
| Nov 3, 2025 | Petersen Floyd F. Director | Sale 10b5-1 plan | 500 | $12.6K |
| Oct 1, 2025 | Petersen Floyd F. Director | Sale 10b5-1 plan | 500 | $13.6K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Amphastar Pharmaceuticals, Inc.
Free account. Everything above stays public.
Write why you follow Amphastar Pharmaceuticals, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading